Top Biotech Earnings Reports to Watch This Week

Health and Healthcare

Published: October 21, 2018 10:15 am

Last Updated: January 11, 2020 4:07 pm

Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week. While health care doesn’t seem to be anywhere near the topic of debate ahead of this election season, it has the potential to be hugely affected by whatever party takes power in the United States.

For the other notable earnings this week, check out the Dow Jones industrials earnings and other major earnings previews.

Note that the earnings and revenue estimates may change ahead of the formal reports, and some companies may reschedule reporting dates as well.

Biogen Inc. (NASDAQ: BIIB) is set to report its most recent results on Tuesday. The consensus estimates from Thomson Reuters call for earnings per share (EPS) of $6.78 and $3.33 billion in revenue. Shares were changing hands at $320.41 on Friday’s close. The 52-week range is $249.17 to $388.67.

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) is scheduled to report its third-quarter results on Wednesday. The consensus estimates are $1.74 in EPS and $1.02 billion in revenue. Shares traded at $125.89 as last week came to a close. The consensus price target is $163.41, and the 52-week trading range is $102.10 to $142.24.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is set to share its latest quarterly earnings on Thursday. The consensus estimates call for a net loss of $0.21 per share on $366.93 million in revenue. Shares were at $103.22 on Friday’s close, in a 52-week range of $75.81 to $106.74. The consensus price target is $120.05.

Bristol-Myers Squibb Co. (NYSE: BMY) is expected to reveal its third-quarter results on Thursday. The consensus forecast calls for $0.91 in EPS, as well as $5.72 billion in revenue. The stock ended last week at $54.30 per share. The consensus price target is $61.59, and the 52-week range is $49.96 to $70.05.

Celgene Corp. (NASDAQ: CELG) also will share its latest quarterly earnings on Thursday. The consensus estimates call for $2.34 in EPS and $1.74 billion in revenue. Shares were at $99.62 as Friday’s trading ended, in a 52-week range of $95.45 to $119.29. The consensus price target is $128.22.

And Gilead Sciences Inc. (NASDAQ: GILD) is expected to reveal its third-quarter results on Thursday as well. The consensus forecast calls for $1.63 in EPS, as well as $5.37 billion in revenue. The stock ended last week at $73.27 per share. The consensus price target is $87.91, and the 52-week trading range is $64.27 to $89.54.

24/7 Wall St.
Jefferies Out With 5 Biotech Stocks Under $10 With Gigantic Upside Potential

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.